Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders

Background Little is known about the endoscopic and histologic findings of non-esophageal eosinophilic gastrointestinal diseases (EGID). Aim To characterize the presenting endoscopic and histologic findings in patients with eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinop...

Full description

Saved in:
Bibliographic Details
Published inDigestive diseases and sciences Vol. 65; no. 7; pp. 2024 - 2035
Main Authors Pesek, Robert D., Reed, Craig C., Collins, Margaret H., Muir, Amanda B., Fulkerson, Patricia C., Menard-Katcher, Calies, Falk, Gary W., Kuhl, Jonathan, Magier, Adam Z., Ahmed, Faria N., Demarshall, Maureen, Gupta, Ankur, Gross, Jonathan, Ashorobi, Tokunbo, Carpenter, Christina L., Krischer, Jeffrey P., Gonsalves, Nirmala, Hirano, Ikuo, Spergel, Jonathan M., Gupta, Sandeep K., Furuta, Glenn T., Rothenberg, Marc E., Dellon, Evan S.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.07.2020
Springer
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Little is known about the endoscopic and histologic findings of non-esophageal eosinophilic gastrointestinal diseases (EGID). Aim To characterize the presenting endoscopic and histologic findings in patients with eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC) at diagnosis and 6 months after initiating the treatment. Methods We conducted a retrospective cohort study at 6 US centers associated with the Consortium of Eosinophilic Gastrointestinal Researchers. Data abstracted included demographics, endoscopic findings, tissue eosinophil counts, and associated histologic findings at diagnosis and, when available, after initial treatment. Results Of 373 subjects (317 children and 56 adults), 142 had EG, 123 EGE, and 108 EC. Normal endoscopic appearance was the most common finding across all EGIDs (62% of subjects). Baseline tissue eosinophil counts were quantified in 105 (74%) EG, 36 (29%) EGE, and 80 (74%) EC subjects. The mean peak gastric eosinophil count across all sites was 87 eos/hpf for EG and 78 eos/hpf for EGE. The mean peak colonic eosinophil count for EC subjects was 76 eos/hpf (range 10–500). Of the 29% of subjects with post-treatment follow-up, most had an improvement in clinical, endoscopic, and histologic findings regardless of treatment utilized. Reductions in tissue eosinophilia correlated with improvements in clinical symptoms as well as endoscopic and histologic findings. Conclusions In this large cohort, normal appearance was the most common endoscopic finding, emphasizing the importance of biopsy, regardless of endoscopic appearance. Decreased tissue eosinophilia was associated with improvement in symptoms, endoscopic, and histologic findings, showing that disease activity is reversible.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Author’s contribution RDP was a consultant for Allakos. MHC was a consultant for Allakos, AstraZeneca, Esocap, Celgene Corporation, Regeneron, and Shire and received research support from Regeneron and Shire. PF was a consultant for Genentech, Inc, and received grant funding from the NIH and research support from Knopp Biosciences, LLC. GF was a consultant for Takeda/Shire and Adare and obtained research support from Takeda/Shire, Celgene, Adare, Regeneron, and Allakos. JMS was a consultant for Regeneron, DBV Technology, and Kaleo and received grant funding from DBV Technology, Aimmune Therapeutics, and Food Allergy Research Education and royalties from UpToDate. NG was in the advisory board for Allakos and obtained royalties from UpToDate. SKG was a consultant for Adare, Alkalos, Abbott, GossamerQOL, and Receptos and obtained research support from Shire and royalties from UpToDate. GF was the founder of EnteroTrack and a consultant for Shire. MER was a consultant for Pulm One, Spoon Guru, Clostrabio, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis, has an equity interest in the first three listed and Immune Pharmaceuticals, and received royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust), and UpToDate. MER is an inventor of patents owned by Cincinnati Children’s. ED was a consultant for Adare, Aimmune, Allakos, Alivio, AstraZeneca, Banner, Biorasi, Calypso, Cel-gene/Receptos, Enumeral, EsoCap, Gossamer Bio, GSK, Regeneron, Salix, and Shire and received research funding from Adare, Allakos, Celegene/Receptos, GSK, Miraca, Meritage, Nutricia, Regeneron, and Shire and educational grant from Allakos, Banner, and Holoclara.
ISSN:0163-2116
1573-2568
1573-2568
DOI:10.1007/s10620-019-05961-4